The State of AI in Pharma 2027
What are the rules?Where can you trust AI?
Pharmaceutical manufacturing and quality, the evidence and workflows they depend on, and the opportunities and limits of AI.
ReportEdition 01

Edition 01
The State of AI in Pharma 2027
Report
Trusted by the teams making the world's medicine.
Inside the report
Three parts: the rules, the evidence, the work.
Each chapter sets out what is established, where AI may help, and what remains to be demonstrated.
Get the ReportThe State of AI in Pharma 2027
Contents
- Introduction
What AI-containing submissions tell us about pharma
- Regulatory status at a glance
- Part 1
The regulatory position entering 2027
- What FDA and European regulators expect of AI
- Where can you trust it?
- Part 2
The evidence foundation
- Pharmaceutical document digitization: accuracy, integrity, and review
- Operational context: grounding AI in pharmaceutical evidence
- Part 3
Investigation and process improvement
- Deviation investigations: workload, evidence, and judgment
- Yield optimization: from measurement to controlled change
- Closing
What teams should establish before expanding AI use in 2027
The full report
The rules, the evidence and the work, in one report.
Questions
About the report.
Book a demo
See Katalyze on your operation.
Bring the job you want to move forward and the records you'd like connected. Thirty minutes on how Katalyze would do the work, and where your experts come in.
Or, just a quick chat to run through the product, your call.




